Showing 1761-1770 of 5771 results for "".
- Dompé Announces First Patient Enrolled in Phase 3 Trial of Cenegermin in Patients With Severe Sjögren's-Related Dry Eye Diseasehttps://modernod.com/news/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with-severe-sjogrens-related-dry-eye-disease/2480630/Dompé announced that the first patient has been enrolled in its phase 3 clinical trial to evaluate the efficacy and safety of cenegermin in patients with severe Sjögren's-related dry eye disease, a primary symptom of Sjögren's. This trial is part of a program th
- Glaukos Announces Executive Leadership Changeshttps://modernod.com/news/glaukos-announces-executive-leadership-changes/2480628/Glaukos announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022: Joseph Gilliam will assume the new role of President and Chief Operating Officer.
- Alimera Sciences Announces Launch of Iluvien for Uveitis in Spainhttps://modernod.com/news/alimera-sciences-announces-launch-of-iluvien-for-uveitis-in-spain/2480619/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch Iluvien for noninfectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill). Brill has received a positive resolution fo
- Eyenovia Announces Changes to Board of Directorshttps://modernod.com/news/eyenovia-announces-changes-to-board-of-directors/2480618/Eyenovia announced changes to its Board of Directors. Sean Ianchulev, MD, PhD, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director
- Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Modelhttps://modernod.com/news/aldeyra-therapeutics-announces-publication-of-phase-2-clinical-trial-of-reproxalap-in-allergen-chamber-model/2480608/Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data Demonstrating the Clinical Benefit of the Prima System in Dry AMD Patientshttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-demonstrating-the-clinical-benefit-of-the-prima-system-in-dry-amd-patients/2480597/Pixium Vision SA announced the publication of a paper in Nature Communications outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophi
- Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patientshttps://modernod.com/news/nanoscope-therapeutics-announces-fda-clearance-of-ind-for-mco-010-gene-therapy-in-stargardt-macular-degeneration-patients/2480594/Nanoscope Therapeutics announced it received IND clearance from the FDA to begin a phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients. “This is another important milestone for Nanoscop
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq